Galera Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
September 14 2020 - 8:00AM
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage
biopharmaceutical company focused on developing and commercializing
a pipeline of novel, proprietary therapeutics that have the
potential to transform radiotherapy in cancer, today announced that
Mel Sorensen, M.D., President and Chief Executive Officer, will
virtually present at the Oppenheimer Fall Healthcare Life Sciences
& MedTech Summit on Tuesday, September 22, 2020, at 1:40
p.m. EDT.
A live webcast of the presentation will be
accessible from the Investors page of Galera’s website,
investors.galeratx.com. An archived version of the webcast will be
available in the News & Events section of the Investors page of
Galera’s website for 30 days following the event.
About Galera Therapeutics
Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical
company focused on developing and commercializing a pipeline of
novel, proprietary therapeutics that have the potential to
transform radiotherapy in cancer. Galera’s lead product candidate
is avasopasem manganese (GC4419), a highly selective small molecule
superoxide dismutase (SOD) mimetic initially being developed for
the reduction of radiation-induced severe oral mucositis (SOM).
Avasopasem is being studied in the Phase 3 ROMAN trial for its
ability to reduce the incidence and severity of SOM induced by
radiotherapy in patients with locally advanced head and neck cancer
(HNC), its lead indication. It is also being studied in a Phase 2a
multi-center trial in Europe assessing the safety of avasopasem in
patients with HNC undergoing standard-of-care radiotherapy, a Phase
2a trial for its ability to reduce the incidence of esophagitis
induced by radiotherapy in patients with lung cancer and completed
enrollment in a pilot Phase 1/2 trial in combination with
stereotactic body radiation therapy (SBRT) in patients with locally
advanced pancreatic cancer. The FDA granted Fast Track and
Breakthrough Therapy designations to avasopasem for the reduction
of SOM induced by radiotherapy. Galera is headquartered in Malvern,
PA. For more information, please visit www.galeratx.com.
Investor Contacts:Christopher DegnanGalera
Therapeutics, Inc.610-725-1500cdegnan@galeratx.com
Jennifer PorcelliSolebury
Trout646-378-2962jporcelli@soleburytrout.com
Media Contact:Heather Anderson6
Degrees919-827-5539handerson@6degreespr.com
Galera Therapeutics (NASDAQ:GRTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Galera Therapeutics (NASDAQ:GRTX)
Historical Stock Chart
From Sep 2023 to Sep 2024